TABLE 3

In vitro activity of lefamulin and comparator agents against the overall population of S. pneumoniae selected serotypes and resistance subsets

Serotypea (total no. tested/%)MIC result (μg/ml)b
LefamulinPENCROERYCLILEVTETTMP-SMX
50%90%50%90%50%90%50%90%50%90%50%90%50%90%50%90%
All (822)0.120.25≤0.034≤0.061≤0.06>8≤0.25>1110.5>8≤0.54
    19A (123/15.0)0.120.254412>8>8>1>111>8>84>4
    3 (70/8.5)0.060.12≤0.03≤0.03≤0.06≤0.06≤0.060.12≤0.25≤0.25110.5>8≤0.5≤0.5
    35B (54/6.6)0.120.2522118>8≤0.25≤0.25110.50.5≤0.5>4
    6C/6D (53/6.4)0.120.250.1210.250.5≤0.068≤0.25≤0.25110.50.5≤0.5>4
    22A/22F (48/5.8)0.120.25≤0.03≤0.03≤0.06≤0.06≤0.068≤0.25≤0.25110.50.5≤0.5≤0.5
    11A/11D (47/5.7)0.250.5≤0.03≤0.03≤0.06≤0.06≤0.068≤0.25≤0.25110.50.5≤0.5≤0.5
    15A/15F (45/5.5)0.120.250.250.250.120.5>8>8>1>111>8>8≤0.54
    7F (45/5.5)0.120.25≤0.03≤0.03≤0.06≤0.06≤0.06≤0.06≤0.25≤0.25110.50.5≤0.5≤0.5
    15B/15C (39/4.7)0.120.25≤0.030.5≤0.060.12≤0.06>8≤0.25≤0.25110.5>8≤0.54
    19F (24/2.9)0.120.25≤0.0340.254≤0.06>8≤0.25>1110.5>8≤0.5>4
    Otherc (274/33.3)0.120.25≤0.030.25≤0.060.12≤0.068≤0.25≤0.25110.50.5≤0.52
MDRd (180/21.9)0.120.252412>8>8>1>111>8>84>4
Non-MDR (642/78.1)0.120.25≤0.031≤0.060.5≤0.068≤0.25≤0.25110.50.5≤0.52
  • a The 13-valent conjugate vaccine contains coverage against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

  • b PEN, penicillin; CRO, ceftriaxone; ERY, erythromycin; CLI, clindamycin; LEV, levofloxacin; TET, tetracycline; TMP-SMX, trimethoprim-sulfamethoxazole.

  • c This catagory comprises 28 serotypes including those that are nontypeable.

  • d MDR, multidrug-resistant (i.e., isolates displaying a resistance phenotype to at least three drug classes). This includes the following serotypes/serogroups (no.): 19A (81), 15A/F (42), 15B/15C (10), 19F (11), nontypeable (7), 6C/6D (5), 23A (5), 3 (3), 9N/9L (3), 23F (3), 14 (3), 35B (2), 21 (1), 22F/22A (1), 6A (1), 7F (1), and 34 (1).